Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells.
The aim of this study was to develop anti-EGFR antibody conjugated poly(lactide-co-glycolide) nanoparticles (NPs) to target epidermal growth factor receptor, highly expressed on non-small cell lung cancer cells to improve cytotoxicity and site specificity. Cetuximab was conjugated to docetaxel (DTX) loaded PLGA NPs by known EDC/NHS chemistry and characterised for size, zeta potential, conjugation efficiency and the results were 128.4 ± 3.6 nm, -31.0 ± 0.8 mV, and 39.77 ± 3.4%, respectively. In vitro release study demonstrated sustained release of drug from NPs with 25% release at pH 5.5 after 48 h. In vitro cytotoxicity studies demonstrated higher anti-proliferative activity of NPs than unconjugated NPs. Cell cycle analysis and apoptosis study were performed to evaluate extent of cell arrest at different phases and apoptotic potential for the formulations, respectively. In vivo efficacy study showed significant reduction in tumour growth and so antibody conjugated NPs present a promising active targeting carrier for tumour selective therapeutic treatment.
['Patel|Jitendrakumar|J|', 'Amrutiya|Jitendra|J|', 'Bhatt|Priyanka|P|', 'Javia|Ankit|A|', 'Jain|Mukul|M|', 'Misra|Ambikanandan|A|']
D000072283:A549 Cells D000818:Animals D000970:Antineoplastic Agents D017209:Apoptosis D000068818:Cetuximab D000077143:Docetaxel D004337:Drug Carriers D016503:Drug Delivery Systems D066246:ErbB Receptors D005260:Female D006801:Humans D018796:Immunoconjugates D019344:Lactic Acid D008175:Lung Neoplasms D016513:Mice, SCID D011100:Polyglycolic Acid D000077182:Polylactic Acid-Polyglycolic Acid Copolymer D043823:Taxoids
Antibody docetaxel poly(lactide-co-glycolide) epidermal growth factor receptor cetuximab